Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Yindan Pinggan** (also known as Yinhua Pinggan or YHPG) is a traditional Chinese medicine (TCM) formulation available as capsules or granules, approved by China's National Medical Products Administration (Drug Approval No. Z20184088). It specializes in soothing damp-heat in the liver and gallbladder, treating conditions like chronic hepatitis, fatty liver, bad breath, and hangover symptoms, while exhibiting anti-inflammatory, antibacterial, antiviral, and antioxidant effects. Clinical trials demonstrate its efficacy as an adjunct to conventional therapy for community-acquired pneumonia (CAP), improving cure rates, reducing CRP levels, shortening hospital stays, and lowering adverse events, with key active components including luteolin, kaempferol, quercetin, rutin, and ellagic acid that inhibit pro-inflammatory pathways such as TNF signaling and NF-κB.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yindan Pinggan.